$CLOV

Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value

Clover Health (CLOV) announced its 2027 Medicare Advantage plans, emphasizing PPO choice, preventive care, and member value. The plans feature low premiums, no referrals, and benefits like routine dental and vision. Clover Assistant, the company's technology, supports physicians in identifying care needs. The plans will be available to 5.2 million Medicare-eligible beneficiaries across 203 counties in five states.

Original reporting
Published Oct 1, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
4/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The announcement provides fresh product details but no financial guidance, limiting immediate trading relevance.

02

Market read

Provides incremental information for investors tracking Medicare Advantage providers; unlikely to trigger significant price movement.

03

What to watch

Potential regulatory scrutiny of low‑premium offerings and the need for sustained provider network support.

Relevance 4/10Novelty 3/10Timing: ahead of the 2027 enrollment period starting Oct 15

Background

Clover Health is a physician‑enablement technology firm offering Medicare Advantage PPO and HMO plans. The 2027 lineup emphasizes low‑cost options and preventive‑care benefits.

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health announced its 2027 Medicare Advantage plan lineup, including a $0‑premium PPO and expanded benefits, marking the first public disclosure of these offerings.

Expected impact

likely modest upside as investors price in expanded market coverage and competitive positioning

Evidence & confidence

The announcement adds new product information but lacks concrete financial metrics or large‑scale contracts; market reaction is expected to be limited.

Market effects

Adds competitive pressure in the Medicare Advantage space, but no immediate sector‑wide shift.

Focused on New Jersey and Georgia markets; limited broader regional effect.

Minimal global impact; primarily a U.S. healthcare niche.

Counterpoint

The plan rollout may strain margins if premium discounts erode profitability, outweighing enrollment gains.

Key entities

  • Clover Health Investments, Corp.

    NASDAQ‑listed provider of Medicare Advantage plans and health‑tech platform.

  • Jamie Reynoso

    CEO of Medicare Advantage at Clover Health, quoted on plan strategy.

Related articles

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$CLOVHigh

Why Is Clover Health (CLOV) Stock Soaring Today

Clover Health (CLOV) stock rose 10.7% premarket after CMS awarded its PPO Medicare Advantage plans a 5-Star rating and HMO plans a 4.5-Star rating for 2027. The ratings, excluding disputed measures, boost payments and enrollment. Shares later cooled to $4.81, up 5%. CLOV is up 99.5% YTD but still below its 52-week high.

$CLOVMed

Is Clover Health Stock Too Dependent On One Group Of Members?

Clover Health Investments (CLOV) reported that nearly half of its Medicare Advantage members joined in 2025 or 2026, impacting short-term profits. Membership grew 48% YoY to 157,000, with new members accounting for 49%. Despite a 70% stock return over 12 months, CLOV's revenue declined 0.7%, and gross profit grew slower than revenue. Management raised full-year guidance but cautioned about future trends.

$CLOVMed

Clover Health Medicare Advantage PPO Plans Earn 5-Star Rating; HMO at 4.5 Stars

Clover Health's PPO Medicare Advantage plans received a 5.0 Star rating and HMO plans 4.5 Stars for 2027, impacting 2028 payments. CMS removed 20 measures for PPO plans, raising their rating. Clover's MA membership grew ~48% YoY to >157,000 members, with 98% in PPO plans. The company ranked #1 among non-SNP PPO plans with >2,000 members on core HEDIS measures, scoring 4.82 out of 5.